Shares of Spanish plasma-derived medicines specialist Grifols rose 9% yesterday after it announced results for the first half ...

The US Food and Drug Administration has set prescription drug user fee rates for fiscal year 2026, with increases across all ...

Bristol Myers Squibb (NYSE: BMY) has posted better-than-expected second-quarter 2025 results, driven by strong sales of its ...

Endometriosis remains a complex challenge for patients and drug developers, with GlobalData highlighting five major gaps ...

Shares in French pharma major Sanofi were 6% lower late Thursday after the presentation of the company’s second quarter ...

Shares of US pharma major AbbVie were up 6.1% at $200.96 in pre-market activity, as it announced second-quarter 2025 ...

The hidradenitis suppurativa (HS) market across the seven major pharmaceutical markets (7MM) is projected to grow from $1.84 ...

As Indian drug manufacturers cry foul over the surge of cheap Chinese pharmaceutical raw material imports, the Indian ...

Japan’s Eisai and US biotech major Biogen have announced that the latest findings demonstrating the benefits of continuous ...

US pharma major AbbVie is considering a $1-billion acquisition of Gilgamesh Pharmaceuticals, Bloomberg News reported on Wednesday, citing people familiar with the matter.

Ipsen (Euronext: IPN) has reported second-quarter sales of 901 million euros ($980 million), up 8% from the same period a ...

UCB, Belgium’s largest drugmaker, today released financial results for first half 2025, showing total revenue in increased to ...